Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Core Insights - Arcutis Biotherapeutics, Inc. has partnered with professional football player Odell Beckham Jr. to raise awareness about seborrheic dermatitis, a common inflammatory skin disease affecting around 10 million Americans [1][5] - The partnership aims to educate the public on the condition and promote ZORYVE foam, a new treatment option for seborrheic dermatitis [4][5] Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases [12] - The company has a growing portfolio that includes three FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions [12] Product Information - ZORYVE foam (0.3%) is indicated for the treatment of seborrheic dermatitis in patients aged 9 years and older [7][8] - Clinical trials showed that nearly 80% of patients using ZORYVE achieved clear or almost clear skin at Week 8, compared to 53% using a vehicle [3] - ZORYVE is a steroid-free topical foam that can be applied to various body areas, including the scalp and face [3][5] Market Context - Seborrheic dermatitis is the third most common skin condition affecting Black individuals, highlighting the need for targeted awareness and treatment options [5] - The condition can significantly impact quality of life, emotional well-being, and self-esteem, making effective treatment crucial [4]